 |
| Photo by Jon Akira Yamamoto/Gamma-Rapho via Getty Images |
This delayed treatment for Asian, Black, and Hispanic patients
Blood oxygen monitors said that hospitalized Asian, Black, and Hispanic COVID-19 patients had higher blood oxygen levels than they actually did, according to a new study. Oxygen levels are an important indicator of how serious someone’s case of COVID-19 is and what medications they’re eligible for — and that overestimation meant that it took longer for Black and Hispanic patients to get necessary treatment. Pulse oximeters, the standard way clinics and hospitals measure blood oxygen, work by sending red and infrared light through the fingertip and measuring the amount that’s reflected back. (Hemoglobin, the protein in blood that carries oxygen, absorbs more infrared light when it’s carrying oxygen).
For years, studies have shown that those devices don’t work as well on people with darker skin. In this new study published in the journal JAMA Internal Medicine, a research team looked at patients with COVID-19 in the Johns Hopkins Health System between March 2020 and November 2021.
Just over 1,200 patients had oxygen levels checked by both pulse oximeters and a more-accurate blood test. In around 30 percent of Asian, Black, and Hispanic patients, the blood test showed low blood oxygen levels when the pulse oximeter said the levels were normal. That was the case for only 17 percent of white patients. In a larger group of over 6,600 patients, the research team found 1,903 patients where a model showed that their oxygen levels would have dropped before the pulse oximeter showed it had. In that group, Black and Hispanic patients were more likely to have had delays in receiving treatments like remdesivir (which most hospitals only gave to patients with oxygen levels below 94 percent) or dexamethasone (which most hospitals only gave to patients who were on supplemental oxygen). Of that group, 451 patients were never flagged as eligible for treatment. More than half of those patients were Black. It took Black patients who did eventually get treatments around one hour longer than white patients to be flagged as eligible.
Other research over the past few years has come to similar conclusions. One study published in November 2021, for example, also showed that gaps between oxygen levels measured on a blood test and on a pulse oximeter were more likely for non-white patients in hospitals than for white patients. Patients with that gap were more likely to have problems with organs and to die in the hospital. The Food and Drug Administration warned in February 2021 that pulse oximeter readings had “limitations” and that skin color can affect readings.
But despite the well-documented inadequacies, there haven’t been major steps to correct the bias, researchers wrote in an editorial accompanying the new study. “Hospitals and practitioners continue to buy and use these devices despite their inaccuracy for non-White patients,” they said. It’s not an easy problem to fix, and pulse oximeters are overall a less precise measure of oxygen in the blood. But hospitals and regulators should push to only allow devices that perform the same across skin tones, and doctors can adjust their treatment practices to recognize the potential errors in their non-white patients. “Although the device measurement error is real and based purely on optics, the decision to do nothing about a faulty device is a human one, and one that can and should be corrected,” they wrote.
EmoticonEmoticon